Efficacy of bromocriptine administration for selective pituitary resistance to thyroid hormone.
The relation between thyroid-stimulating hormone (TSH) and triiodothyronine (T3) was evaluated in a girl with the selective pituitary type of thyroid hormone resistance for more than 7 years to clarify whether bromocriptine was an effective treatment or not. Levels of T3 (before: 2.44 +/- 0.64 nmol/l, mean +/- SD) and TSH (4.81 +/- 2.52 mU/l) were significantly decreased during therapy (T3: 2.15 +/- 0.44 nmol/l; TSH: 1.59 +/- 0.78 mU/l). T3 x TSH, calculated as one of the indices of pituitary resistance, on bromocriptine therapy (3.229 +/- 1.255 mU/l x nmol/l) was significantly (p < 0.005) smaller than the product before the administration (11.298 +/- 5.891 mU/l x nmol/l). The results suggest that bromocriptine should be one of the agents initially considered for the treatment of pituitary resistance to thyroid hormone.
Ohzeki
T
T
Department of Pediatrics, Faculty of Medicine, Tottori University, Yonago, Japan.
Hanaki
K
K
Motozumi
H
H
Ohtahara
H
H
Ishitani
N
N
Urashima
H
H
Tsukuda
T
T
Shiraki
K
K
Sasaki
S
S
Nakamura
H
H
D001971:Bromocriptine / Q000627:therapeutic use*; D002648:Child; D004351:Drug Resistance; D005260:Female; D006801:Humans; D006980:Hyperthyroidism / Q000188:drug therapy* / Q000503:physiopathology; D010902:Pituitary Gland / Q000187:drug effects* / Q000503:physiopathology*; D013963:Thyroid Hormones / Q000502:physiology*; D013972:Thyrotropin / Q000097:blood; D014284:Triiodothyronine / Q000097:blood
D013963:Thyroid Hormones; D014284:Triiodothyronine; D001971:Bromocriptine; D013972:Thyrotropin